Kanamori Hiroki, Yasuhara Hisae, Mashima Souichiro, Suto Kozue, Yamauchi Kenji, Akita Mitsuhiro, Jinno Hideki, Hata Hidenori, Nakatsu Morihito, Ando Masaharu
Department of Gastroenterology, Mitoyo General Hospital.
Nihon Shokakibyo Gakkai Zasshi. 2019;116(3):235-240. doi: 10.11405/nisshoshi.116.235.
A 74-year-old male with lung squamous cell carcinoma who was treated with the anti PD-1 antibody nivolumab developed frequent diarrhea four months after initiating treatment. However, his condition did not improve despite prednisolone at 20mg. Endoscopic examination revealed loss of vascular pattern, erosions, and mucosal friability, resembling ulcerative colitis. Colonoscopy revealed punch-out ulcers in the affected mucosa. Therefore, he was definitively diagnosed with severe colitis caused by immune checkpoint inhibitor treatment and cytomegalovirus colitis. Nivolumab was discontinued, and he was treated with 60mg prednisolone and ganciclovir. Although his colitis improved, he developed pneumonia and died thereafter. This case highlights adverse events that are associated with immune checkpoint inhibitors which should be treated properly.
一名74岁的肺鳞状细胞癌男性患者,在开始使用抗PD-1抗体纳武单抗治疗四个月后出现频繁腹泻。然而,尽管使用了20mg泼尼松龙,他的病情仍未改善。内镜检查显示血管纹理消失、糜烂和黏膜脆性增加,类似于溃疡性结肠炎。结肠镜检查发现受累黏膜有穿孔性溃疡。因此,他被明确诊断为免疫检查点抑制剂治疗引起的严重结肠炎和巨细胞病毒性结肠炎。纳武单抗停药,他接受了60mg泼尼松龙和更昔洛韦治疗。尽管他的结肠炎有所改善,但随后他患上了肺炎并死亡。该病例突出了与免疫检查点抑制剂相关的不良事件,应妥善处理。